Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Akebia Therapeutics (AKBA) over the last 9 years, with Q1 2024 value amounting to $43.3 million.

  • Akebia Therapeutics' Non-Current Deffered Revenue changed 0.0% to $43.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $43.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $43.3 million for FY2023, which is 0.0% changed from last year.
  • As of Q1 2024, Akebia Therapeutics' Non-Current Deffered Revenue stood at $43.3 million, which was down 0.0% from $43.3 million recorded in Q4 2023.
  • In the past 5 years, Akebia Therapeutics' Non-Current Deffered Revenue ranged from a high of $65.4 million in Q1 2022 and a low of $16.6 million during Q2 2021
  • In the last 5 years, Akebia Therapeutics' Non-Current Deffered Revenue had a median value of $43.3 million in 2022 and averaged $37.3 million.
  • Per our database at Business Quant, Akebia Therapeutics' Non-Current Deffered Revenue crashed by 5490.78% in 2021 and then soared by 23864.97% in 2022.
  • Akebia Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $25.3 million in 2020, then fell by 15.27% to $21.5 million in 2021, then surged by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
  • Its last three reported values are $43.3 million in Q1 2024, $43.3 million for Q4 2023, and $43.3 million during Q3 2023.